TCGX Acquisition (TCGX) Stock News
$TCGX · NASDAQ · 1 stories in 30 days$13.14
1D +7.18%
BORSA has published 1 story on TCGX Acquisition (TCGX) in the past 30 days. BORSA’s news read on TCGX is bullish at 77/100, based on 1 company event over the past 7 days.
The wire on $TCGX
newest first · updated · direct subject stories onlyTriGemX Bio and TCGX Acquisition Corp. announce business combination agreement for migraine drug
TriGemX Bio and SPAC TCGX Acquisition Corp. (TCGX) announced a definitive business combination. The combined company will trade as TGEM on Nasdaq. The deal includes a $160 million PIPE and ~$246 million in gross proceeds to fund Phase 3 trials of elismetrep, a potential first-in-class migraine treatment. Expected close in Q1 2027.
neutral 50 · impact 60